Buprenorphine-induced Symptomatic Hypogonadism in Men: Case Reports and Discussion

Journal of Addiction Medicine

Volumn 2, Issue 3, 2008, Pages 147-150

  Colameco, Stephen ^c   Coren, Joshua S ^a   Zimmerman, Daniel J ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UMDNJ School of Osteopathic Medicine   (United States)

^c Addiction Pain Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68149113356     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318172d612     Document Type: Article

References (20)

1. Azizi F, Vagenakis AG, Longcope C, et al. Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids. 1973;22:467-472.
2. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther. 1975;192:211-217.
3. Cicero TJ, Bell RD, Wiest WG, et al. Function of the male sex organs in heroin and methadone users. N Engl J Med. 1975;292:882-887.
4. Hanbury R, Cohen M, Stimmel B. Adequacy of sexual performance in men maintained on methadone. Am J Drug Alcohol Abuse. 1977;4:13-20.
5. Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiol Clin North America. 2003;21:699-713.
6. Daniell HW. Sex hormone deficiency in depressed patients receiving opioids. Arch Int Med. 2004;164:804-804
7. Kalyani RR, Gaviine S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007;36:333-348.
8. Finch PM, Roberts LJ, Price L, et al. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000;16:251-254.
9. Rajagopal A, Vassiloopoulou-Sellin R, Palmer TJ, et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opiates. Cancer. 2004;100:851-858.
10. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377-384.
11. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7:901-907.
12. Bliesener N, Albrecht S, Schwager A, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90:203-206.
13. Romero DV, Partilla JS, Zheng QX, et al. Opioid peptide receptor studies: buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay. Synapse. 1999;34:83-94.
14. Rothman RB, Gorelick DA, Heishman SJ, et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abuse Treat. 2000;8:277-281.
15. Dragatsis I, Papazafri P, Zioudrou C, et al. Opioids modify the release of LH at the pituitary level: in vitro studies with entire rat pituitaries. J Endocrinol. 1995;145:263-270.
16. Bliesener N, Albrecht S, Schwager A, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90:203-206.
17. Ciraulo DA, Hitzemann RJ, Eugene Somoza E, et al. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol. 2006;46:179-192.
18. Schmittner J, Schoeder JR, Epstein DH, et al. Menstrual cycle length during methadone maintenance. Addiction. 2005;100:829-836.
19. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215-2222.
20. Krams ES. Intraspinal opioid therapy for chronic nonmaligant pain: current practice and clinical guidelines. J Pain Symptom Manage. 1996;11:333-352.